BofA analyst Michael Ryskin raised the firm’s price target on Danaher to $280 from $250 and keeps a Neutral rating on the shares after the company reported Q2 results. The firm thinks “it is too early to turn bullish” on Danaher as 2024 numbers are still moving lower and it sees risk that headwinds persist into 2024 and lead to even further downward revisions, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher price target raised to $290 from $260 at Barclays
- Danaher Corporation Earnings Update: Did it Beat Estimate Forecasts?
- Beckman Coulter receives FDA clearance for DxC 500 AU Chemistry Analyzer
- Danaher sees Q3 base business core revenue down low-single digits
- Danaher reports Q2 adjusted EPS $2.05, consensus $2.01